Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile

Simple item page
dc.contributor.authorJara, Alejandro
dc.contributor.authorUndurraga, Eduardo A.
dc.contributor.authorZubizarreta, Jose R.
dc.contributor.authorGonzalez, Cecilia
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorPizarro, Alejandra
dc.contributor.authorVergara, Veronica
dc.contributor.authorSoto-Marchant, Mario
dc.contributor.authorGilabert, Rosario
dc.contributor.authorFlores, Juan Carlos
dc.contributor.authorSuarez, Pamela
dc.contributor.authorLeighton, Paulina
dc.contributor.authorEguiguren, Pablo
dc.contributor.authorCarlos Rios, Juan
dc.contributor.authorFernandez, Jorge
dc.contributor.authorGarcia-Escorza, Heriberto
dc.contributor.authorAraos, Rafael
dc.date.accessioned2024-01-10T13:10:34Z
dc.date.available2024-01-10T13:10:34Z
dc.date.issued2022
dc.description.abstractThe outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3-5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac's inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5-39.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6-75.2) against hospitalization and 69.0% (95% CI, 18.6-88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3-5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.
dc.description.abstractCoronaVac protects young children from severe COVID-19 during a SARS-CoV-2 Omicron surge, supporting the effectiveness and importance of vaccinating this pediatric population.
dc.fechaingreso.objetodigital2024-04-25
dc.fuente.origenWOS
dc.identifier.doi10.1038/s41591-022-01874-4
dc.identifier.eissn1546-170X
dc.identifier.issn1078-8956
dc.identifier.urihttps://doi.org/10.1038/s41591-022-01874-4
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/77886
dc.identifier.wosidWOS:000811448200001
dc.information.autorucFacultad de Medicina; Rios Bustamante, Juan Carlos; S/I; 104168
dc.information.autorucInterdisciplinarias; Undurraga Fourcade, Eduardo Andres; S/I; 12868
dc.language.isoen
dc.nota.accesocontenido completo
dc.publisherNATURE PORTFOLIO
dc.rightsacceso abierto
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEffectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile
dc.typeartículo
sipa.codpersvinculados104168
sipa.codpersvinculados12868
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.pdf
Size:
3.78 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas